Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PGD | P52209 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 3/20 | 0.31 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30413464 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL16349539 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL30692679 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL4724595 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL1569332 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL20576207 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL31465077 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL30891962 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL2912046 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL489239 | 1.00 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025094117-A1 | SUBSTITUTED INDOLYL COMPOUNDS, COMPOSITIONS THEREOF, AND THERAPEUTIC USES THEREOF | GT GAIN THERAPEUTICS SA (CH) | 2025-05-08 | — | — | WO | claimed |
| WO-2023042177-A1 | ENANTIOMERS OF 5-((7-CHLOROISOQUINOLIN-1-YL)AMINO)-N-(6-METHOXY-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)PICOLINAMIDE | GT GAIN THERAPEUTICS SA (CH) | 2023-03-23 | — | — | WO | claimed |
| US-11440898-B2 | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase | MINORYX THERAPEUTICS S.L. (ES) | 2022-09-13 | — | — | US | claimed |
| WO-2025094117-A1 | SUBSTITUTED INDOLYL COMPOUNDS, COMPOSITIONS THEREOF, AND THERAPEUTIC USES THEREOF | GT GAIN THERAPEUTICS SA (CH) | 2025-05-08 | — | — | WO | disclosed |
| CN-115348959-B | Heteroaryl compounds and their therapeutic use in conditions associated with altered beta-glucocerebrosidase activity | GT增益治疗股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2023042177-A1 | ENANTIOMERS OF 5-((7-CHLOROISOQUINOLIN-1-YL)AMINO)-N-(6-METHOXY-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)PICOLINAMIDE | GT GAIN THERAPEUTICS SA (CH) | 2023-03-23 | — | — | WO | disclosed |
| US-11440898-B2 | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase | MINORYX THERAPEUTICS S.L. (ES) | 2022-09-13 | — | — | US | disclosed |
| CN-114929287-A | Compositions and methods for treating hepatitis B | 比姆医疗股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. | 2022-06-16 | — | — | US | disclosed |
| CN-114206395-A | Method for editing single nucleotide polymorphisms using a programmable base editor system | 比姆医疗股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114190093-A | Disruption of splice acceptor sites of disease-associated genes using adenylate deaminase base editor, including use in treating genetic diseases | 比姆医疗股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-114173820-A | Methods and compositions for treating autoimmune diseases | 美真达治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-1862455-A2 | 11-((4R,6R)-4,5,6-trihydroxy-3-(R)-hydroxy-2-(S)-hydroxy-hexylcarbamoyl)-undecanoic acid | Sanofi-Aventis Deutschland GmbH (DE) | 2007-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440898-B2 | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase | GLB1, GBA1, GALC | PDE4A 1739/4885LMNA 139/4885L3MBTL1 381/4885 |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | GAA, GBA1, GBA2 | PDE4A 1828/4885LMNA 1299/4885L3MBTL1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.